Comparative Pharmacology
Head-to-head clinical analysis: AFAXIN versus AMNESTEEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFAXIN versus AMNESTEEM.
AFAXIN vs AMNESTEEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of the sodium-dependent serotonin reuptake transporter (SERT), increasing serotonin levels in the synaptic cleft.
Retinoid that binds to and activates retinoic acid receptors (RARs), thereby normalizing keratinocyte differentiation and reducing sebum production.
500 mg orally twice daily
0.5-1.0 mg/kg/day orally in 2 divided doses
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; prolonged in renal impairment (up to 30 hours).
Terminal elimination half-life: 10-20 hours (mean 17 hours) in patients with normal renal function; prolonged in severe renal impairment
Clinical Note
moderateVenlafaxine + Desmopressin
"The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desmopressin."
Clinical Note
moderateDesvenlafaxine + Desmopressin
"The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Desmopressin."
Clinical Note
moderateDesvenlafaxine + Haloperidol
"The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Haloperidol."
Clinical Note
moderateRenal excretion accounts for approximately 60-70% of the administered dose as unchanged drug; biliary/fecal elimination accounts for 20-25% with the remainder as metabolites.
Renal (65-83% as unchanged drug and metabolites), fecal (15-35% as metabolites)
Category C
Category C
Retinoid
Retinoid
Venlafaxine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Venlafaxine."